|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7959 ) in heahhy subjects显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 2 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 3 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban ( BAY 59-7939 ) in healthy subjects显示文摘 | KUBITZA D BECKA M ZUEHLSDORF M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 4 | Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects显示文摘 | Dagmar Kubitza Michael Becka Georg Wensing Barbara Voith Michael Zuehlsdorf | 2005 | European Journal of Clinical Pharmacology2005，，12： | 1 |
| 5 | Body weight has limited influence on the safety, tolerability, pharma- cokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | J Clin Pharmacol2007，47，3： | 1 |
| 6 | No interac- tion between the novel oral direct factor Xa inhibitor BAY 59-7939 and digoxin 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2006 | J Clin Pharm2006，46，8： | 1 |
| 7 | Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 ( rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2006 | J Clin Pharmacol2006，46，5： | 1 |
| 8 | Effect of food an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59 -7939 (rivaroxaban), an oral direct factor Xa inhibitor, in healthy subjects显示文摘 | KUBITZA D BECKA M ZUEHLSDORF M | 2006 | J Clin Phamacol2006，46，5： | 1 |
| 9 | Rivaroxaban(BAY59-7939) -an o- ral direct factor Xa inhibitor-has no clinically relevant interaction with naproxen 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | Br J Clin Pharmacol2007，63，4： | 1 |
| 10 | Effect of food, anantacid, and the H2 antagonist ranitidine on the absorptionof BAY 59-7939 (rivaroxaban), an oral, direct factor Xainhibitor, in healthy subjects 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2006 | J Clin Pharmacol2006，46，5： | 1 |
| 11 | Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa in- hibitor, in healthy subjects 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2006 | J Clin Pharmacol2006，46，5： | 1 |
| 12 | No interaction between the novel oral direct Factor Xa inhibitor BAY 59-7939 and digoxin 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2006 | J Clin Pharmaco12006，，： | 1 |
| 13 | Effect of food, an antacid, and the H 2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjeets显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2006 | J Clin Pharmaeol2006，46，5： | 1 |
| 14 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939 ) in healthy subjects显示文摘 | KUBITZA D BECKA M ZUEHLSDORF M | 2007 | J Clin Pharmacol2007，47，3： | 1 |
| 15 | Body weight has limited influence on the safety,tolerability,pharmacokinetics,or pharmacodynamics of rivaroxaban(BAY 59-7939)in healthy subjects显示文摘 | KUBITZA D BECKA M ZUEHLSDORF M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 16 | No interaction between the novel oral direct factor Xa inhibitor BAY 59- 7939 and digoxin显示文摘 | KUBITZA D BECKA M ZUEHLSDORF M | 2006 | J Clin Pharm2006，46，70： | 1 |
| 17 | Body weight has limited influence on the safety,tolerability,pharmacokinetics,or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 18 | Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2006 | J Clin Pharma- col2006，46，5： | 1 |
| 19 | Effect of food,an antacid,and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban),an oral,direct factor Ⅹa inhibitor,in healthy subjects显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2006 | J Clin Pharmacol2006，46，5： | 1 |
| 20 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, orpharmacodynamics of rivaroxaban in healthy subjects 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2013 | J Clin Pharmaco12013，47，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员